Boehringer Ingelheim
MY OFEV Logo

Nintedanib
Nintedanib

Meet-the-Expert with Dr. Oliver Distler: Highlights Report

02/12/2021  |  Author: Boehringer Ingelheim

Document ID: EM-MY-100196

Expert View

FSIN||ILD Talk: The future of treatment for HP
FSIN||ILD Talk: The experts’ practical experience with OFEV® (nintedanib)
FSIN||ILD Talk: How to treat progressive, fibrotic HP
FSIN||ILD Talk: How to monitor patients with HP for progression and identify PPF early
FSIN||ILD Talk: What are the treatment options for patients with HP
FSIN||ILD Talk: Tips for differentiating HP from idiopathic pulmonary fibrosis
FSIN||Optimizing treatment of patients with PF-ILD with patient case study- Expert Lecture
FSIN||Why even wait until there is 10% relative FVC decline? – Physician Perspective video snippet
FSIN||Rationale for early antifibrotic treatment in PF-ILD Video snippet
FSIN||How to Identify Progression in Fibrotic ILD - Radiology Expert Excerpt
Meet-the-Expert with Dr. Oliver Distler: Highlights Report
Meet-the-Expert with Dr. Hoffmann-Vold: Highlights Report
Meet-the-Expert with Dr. Martin Aringer: Highlights Report

RELATED CONTENT